First Time Loading...

Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 83.6 EUR 2.51% Market Closed
Updated: May 12, 2024
Section:
 

Relative Value

The Relative Value of one ROVI stock under the Base Case scenario is 66.66 EUR. Compared to the current market price of 83.6 EUR, Laboratorios Farmaceuticos ROVI SA is Overvalued by 20%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ROVI Relative Value
Base Case
66.66 EUR
Overvaluation 20%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.2
P/S
P/S
Price to Sales
5.2
vs History
9
vs Industry
25
Median 3Y
3.5
Median 5Y
2.7
Industry
2.5
Forward
5.2
More Details
25.4
P/E
P/E
Price to Earnings
25.4
vs History
33
vs Industry
20
Median 3Y
14.1
Median 5Y
20
Industry
23.4
Forward
25
More Details
38.3
P/OCF
P/OCF
Price to OCF
38.3
vs History
22
vs Industry
12
Median 3Y
19.5
Median 5Y
19.5
Industry
17.9
More Details
96.6
P/FCFE
P/FCFE
Price to FCFE
96.6
vs History
6
vs Industry
7
Median 3Y
31.5
Median 5Y
16.3
Industry
24.1
More Details
8
P/B
P/B
Price to Book Value
8
vs History
15
vs Industry
8
Median 3Y
6.6
Median 5Y
5
Industry
2.1
More Details
5.3
EV/S
EV/S
Enterprise Value to Sales
5.3
vs History
9
vs Industry
24
Median 3Y
3.4
Median 5Y
2.6
Industry
2.6
Forward
5.2
More Details
8.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.9
vs History
9
vs Industry
24
Median 3Y
5.7
Median 5Y
4.4
Industry
5.2
More Details
17.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.8
vs History
26
vs Industry
21
Median 3Y
10.6
Median 5Y
13.9
Industry
13.9
Forward
18.2
More Details
19.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
19.8
vs History
39
vs Industry
23
Median 3Y
11.4
Median 5Y
16.4
Industry
17.5
Forward
20.5
More Details
38.5
EV/OCF
EV/OCF
Enterprise Value to OCF
38.5
vs History
22
vs Industry
11
Median 3Y
18.6
Median 5Y
18.6
Industry
16.4
More Details
75.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
75.1
vs History
11
vs Industry
7
Median 3Y
29.6
Median 5Y
18.6
Industry
18.1
More Details
6.5
EV/IC
EV/IC
Enterprise Value to IC
6.5
vs History
22
vs Industry
14
Median 3Y
5.5
Median 5Y
4.1
Industry
1.9
More Details

Multiples Across Competitors

ROVI Competitors Multiples
Laboratorios Farmaceuticos ROVI SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
4.3B EUR 5.2 25.4 17.8 19.8
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
722.3B USD 20.1 117.7 57.6 65.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.8B USD 4.2 9.4 11.6 15.1
US
Merck & Co Inc
NYSE:MRK
329.4B USD 5.4 142.8 35.6 58.1
UK
AstraZeneca PLC
LSE:AZN
191.8B GBP 5 37.9 174.6 278.6
CH
Novartis AG
SIX:NOVN
180.6B CHF 3.4 11.4 8.7 12.6
CH
Roche Holding AG
SIX:ROG
179.5B CHF 3.1 15.6 8.9 10.5
US
Pfizer Inc
NYSE:PFE
158.1B USD 2.9 -511.8 12.7 20.2
P/E Multiple
Earnings Growth
ES
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Average P/E: 50.5
25.4
60%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
117.7
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
142.8
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.9
168%
CH
Novartis AG
SIX:NOVN
11.4
15%
CH
Roche Holding AG
SIX:ROG
15.6
26%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -511.8
680%

See Also

Summary
ROVI intrinsic value, competitors valuation, and company profile.
DCF Valuation
ROVI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ROVI stock valuation using valuation multiples.
Wall Street Estimates
ROVI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ROVI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 136,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.